Bausch Health Cos (NYSE:BHC – Get Free Report) and ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends and institutional ownership.
Valuation & Earnings
This table compares Bausch Health Cos and ARS Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bausch Health Cos | $10.27 billion | 0.21 | $157.00 million | ($2.96) | -1.99 |
| ARS Pharmaceuticals | $84.28 million | 4.63 | -$171.30 million | ($2.18) | -1.80 |
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Bausch Health Cos and ARS Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bausch Health Cos | 1 | 5 | 0 | 1 | 2.14 |
| ARS Pharmaceuticals | 1 | 1 | 4 | 0 | 2.50 |
Bausch Health Cos presently has a consensus target price of $8.00, indicating a potential upside of 35.71%. ARS Pharmaceuticals has a consensus target price of $25.00, indicating a potential upside of 536.94%. Given ARS Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe ARS Pharmaceuticals is more favorable than Bausch Health Cos.
Risk and Volatility
Bausch Health Cos has a beta of 0.37, indicating that its share price is 63% less volatile than the S&P 500. Comparatively, ARS Pharmaceuticals has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500.
Insider and Institutional Ownership
78.7% of Bausch Health Cos shares are held by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are held by institutional investors. 20.7% of Bausch Health Cos shares are held by insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares Bausch Health Cos and ARS Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bausch Health Cos | -10.12% | -561.95% | 6.31% |
| ARS Pharmaceuticals | -184.24% | -256.67% | -69.63% |
Summary
ARS Pharmaceuticals beats Bausch Health Cos on 9 of the 15 factors compared between the two stocks.
About Bausch Health Cos
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
About ARS Pharmaceuticals
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Receive News & Ratings for Bausch Health Cos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Cos and related companies with MarketBeat.com's FREE daily email newsletter.
